Investors Buy Shares of Pfizer (PFE) on Weakness

Traders purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Thursday. $142.15 million flowed into the stock on the tick-up and $59.64 million flowed out of the stock on the tick-down, for a money net flow of $82.51 million into the stock. Of all equities tracked, Pfizer had the 12th highest net in-flow for the day. Pfizer traded down ($0.08) for the day and closed at $35.89

A number of analysts recently commented on PFE shares. Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. restated a “buy” rating on shares of Pfizer in a research report on Tuesday, January 30th. BMO Capital Markets set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, February 15th. SunTrust Banks restated a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Monday, January 29th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research report on Wednesday, January 24th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $40.08.

Get Pfizer alerts:

The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $213.11 billion, a PE ratio of 13.54, a PEG ratio of 1.78 and a beta of 0.89.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The company had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the prior year, the business posted $0.69 EPS. The company’s quarterly revenue was up 1.0% on a year-over-year basis. equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a dividend of $0.34 per share. The ex-dividend date is Thursday, May 10th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.79%. Pfizer’s dividend payout ratio is 51.32%.

In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the transaction, the insider now directly owns 36,959 shares in the company, valued at approximately $1,374,505.21. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Ian C. Read sold 132,312 shares of the stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 380,349 shares of company stock valued at $13,829,340. Company insiders own 0.06% of the company’s stock.

Several institutional investors have recently bought and sold shares of PFE. Security Asset Management lifted its stake in Pfizer by 6.1% in the 4th quarter. Security Asset Management now owns 22,827 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 1,317 shares during the last quarter. Waldron LP lifted its stake in Pfizer by 6.0% in the 4th quarter. Waldron LP now owns 23,785 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 1,341 shares during the last quarter. Community Financial Services Group LLC lifted its stake in Pfizer by 0.6% in the 4th quarter. Community Financial Services Group LLC now owns 216,884 shares of the biopharmaceutical company’s stock valued at $7,856,000 after purchasing an additional 1,375 shares during the last quarter. TCI Wealth Advisors Inc. lifted its stake in Pfizer by 2.0% in the 4th quarter. TCI Wealth Advisors Inc. now owns 71,284 shares of the biopharmaceutical company’s stock valued at $2,582,000 after purchasing an additional 1,375 shares during the last quarter. Finally, Banced Corp lifted its stake in Pfizer by 5.4% in the 4th quarter. Banced Corp now owns 26,667 shares of the biopharmaceutical company’s stock valued at $965,000 after purchasing an additional 1,376 shares during the last quarter. Institutional investors own 69.53% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.